Roche has acquired exclusive commercial rights outside the U.S. to Sarepta Therapeutics’ lead gene therapy pipeline candidate SRP-9001 (AAVrh74.MHCK7.micro-dystrophin) for Duchenne muscular dystrophy (DMD), through a licensing agreement that could generate more than $2.85 billion for Sarepta.
A study reveals the structural maintenance of chromosomes proteins that shape our DNA can switch directions.
Roche has exercised its option to license a novel capsid from Dyno Therapeutics for use in a gene therapy program for an undisclosed neurological disease.
The AI-designed proteins neutralized lethal 3FTx toxins found in snake venom, which are often the reason that traditional antivenoms fail.
Researchers have developed a new microscopic method to observe the interactions of therapeutic antibodies with target molecules on tumor cells.
Depression is a highly prevalent disorder, and researchers still have a lot to learn about its biological underpinnings.
EY—the professional services firm originally known as Ernst & Young—reports the dollar value of biopharma M&A deals nosedived 51% during 2024, to 92 from 186…
Researchers used computer modeling to predict which components of cigarette smoke might be recognized by antigen-presenting molecule MR1.
Researchers say strategy will help understand the history of life, monitor the spread of pathogens or create new treatments for disease.
Two compounds prolonged the survival of photoreceptors in a retinitis pigmentosa mouse model for rod opsin misfolding
The Lonza-Iconovo deal aims to identify the deal product properties concerning particle size, stability, and device compatibility.
